Shome Debraj, Shah Radha Atal, Gowda Dinesh, Vadera Sapna, Kumar Vaibhav, Raj Manish, Atif Ali, Doshi Komal, Vekaria Mrudul, Pathak Meghna, Kapoor Rinky
Department of Facial Plastic Surgery & Facial Cosmetic Surgery, The Esthetic Clinics, Mumbai, India.
Apollo Hospital, Hyderabad, India.
J Cosmet Dermatol. 2021 Aug;20(8):2472-2479. doi: 10.1111/jocd.14249. Epub 2021 Jun 6.
Hyaluronic acid (HA) fillers are quite commonly used since several years for soft tissue augmentation.
The purpose of this study was to evaluate primarily the safety and secondarily the clinical effectiveness of Cross-Linked Sodium Hyaluronate 24 mg with Lidocaine 3 mg (Jeunesso 24L) injection, in subjects undergoing treatment for facial wrinkles and lip augmentation.
Patients between the age groups of 18 and 75 years, who were seeking soft tissue augmentation treatment on the face and with wrinkle severity score (WSS) ≥2 for bilateral Nasolabial Folds (NLF), were included in the study. The appropriate quantity of the filler was injected at the treatment site. Clinical efficacy assessments were conducted independently at 3 and 6 months after baseline. Clinical efficacy was assessed using Wrinkle Severity Rating Scale (WSRS) and a Global Aesthetic Improvement Scale (GAIS).
The mean pain score was found to be 2.57 ± 2.06 immediately after injection which was reduced to 0.1 ± 0.675 at 15 min and this further subsided to "No Pain" in any of the participants at 60 min post the injection. WSRS mean score before treatment was 2.76, which were significantly reduced to 2.14, at 3 months. Majority of participants found an improvement in the marionette line severity. Also, significant improvements were seen in the perioral and lip areas. The Study filler was well-tolerated and no side effects were reported.
The study indicates that this particular filler, HA+L, is useful for cosmetic improvements in the nasolabial folds and for enhancement of the lips.
多年来,透明质酸(HA)填充剂一直被广泛用于软组织填充。
本研究的主要目的是评估交联透明质酸钠24mg与利多卡因3mg(乔雅登24L)注射在面部皱纹治疗和唇部填充受试者中的安全性,其次评估其临床有效性。
年龄在18至75岁之间、寻求面部软组织填充治疗且双侧鼻唇沟(NLF)皱纹严重程度评分(WSS)≥2的患者纳入本研究。在治疗部位注射适量的填充剂。在基线后3个月和6个月独立进行临床疗效评估。使用皱纹严重程度评定量表(WSRS)和整体美学改善量表(GAIS)评估临床疗效。
注射后立即测得的平均疼痛评分为2.57±2.06,15分钟时降至0.1±0.675,注射后60分钟时所有受试者的疼痛进一步减轻至“无痛”。治疗前WSRS平均评分为2.76,3个月时显著降至2.14。大多数受试者发现木偶纹严重程度有所改善。此外,口周和唇部区域也有显著改善。研究中的填充剂耐受性良好,未报告任何副作用。
该研究表明,这种特定的填充剂HA+L可用于改善鼻唇沟外观和丰唇。